AbbVie Biologics Manufacturing Facility Construction

Deal value: $1,200,000,000

AbbVie announced construction of a new biologics manufacturing facility in Worcester, Massachusetts, featuring 300,000 SF of advanced cleanroom and cell culture space.

AbbVie is investing $70 million in Worcester biologics manufacturing expansion as part of a broader $10 billion U.S. capital commitment to meet surging global demand for oncology and immunology medicines. The investment reflects strategic repositioning to localize production, reduce supply chain vulnerability post-pandemic, and capitalize on strong market growth in complex biologics. The facility will enable transfer of select oncology products from Europe to the U.S., improving production velocity and regulatory control while supporting next-generation therapeutic development.